Age, ≥60 vs. <60 y | 1.23 (0.38–3.95) | 0.729 | | |
Sex, female vs. male | 0.38 (0.05–2.93) | 0.354 | | |
ECOG, 1/2 vs. 0 | 0.99 (0.33–2.98) | 0.985 | | |
AJCC stage, III/IV vs. I/II | 2.09 (0.72–6.05) | 0.176 | | |
CLIP score, >1 vs. ≤1 | 1.87 (0.62–5.65) | 0.266 | | |
Child–Pugh B vs. A | 0.04 (0.01–471.94) | 0.509 | | |
AFP, >100 vs. ≤100 ng/mL | 1.05 (0.33–3.34) | 0.941 | | |
SABR dose, >40 vs. ≤40 Gy | 0.96 (0.33–2.78) | 0.942 | | |
Tumor volume, >40 vs. ≤40 cm3 | 2.65 (0.83–8.47) | 0.100 | 1.79 (0.44–7.39)† | 0.419 |
Visual 18F-FDG uptake, + vs. − | 2.24 (0.77–6.47) | 0.138 | 1.95 (0.50–7.52) | 0.334 |
TSUVmax, >3.2 vs. ≤3.2 | 4.99 (1.10–22.51) | 0.037 | 9.40 (1.18–74.76) | 0.034 |
TSUVmean, >2.9 vs. ≤2.9 | 1.38 (0.48–3.98) | 0.552 | 1.31 (0.42–4.06) | 0.644 |
TSUVmax/LSUVmax, >1.15 vs. ≤1.15 | 2.23 (0.74–6.71) | 0.152 | 1.61 (0.45–5.71) | 0.461 |
TSUVmax/LSUVmean, >1.25 vs. ≤1.25 | 2.43 (0.68–8.75) | 0.173 | 1.31 (0.28–6.07) | 0.734 |
CT/18F-FDG PET score, >4 vs. ≤4 | 5.23 (1.17–23.47) | 0.031 | 4.96 (1.05–23.40)† | 0.043 |